Evidence map›Paper›PMID 38798647›Full record

ArticlebioRxiv : the preprint server for biology2024

Radiation-Induced Cellular Plasticity: A Strategy for Combatting Glioblastoma.

Ling He, Daria Azizad, Kruttika Bhat, Angeliki Ioannidis, Carter J Hoffmann, Evelyn Arambula, Aparna Bhaduri, Harley I Kornblum, Frank Pajonk

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Ling HeDepartment of Radiation Oncology, David Geffen School of Medicine at UCLA.
Daria AzizadDepartment of Biological Chemistry at UCLA.
Kruttika BhatDepartment of Radiation Oncology, David Geffen School of Medicine at UCLA.
Angeliki IoannidisDepartment of Radiation Oncology, David Geffen School of Medicine at UCLA.
Carter J HoffmannDepartment of Radiation Oncology, David Geffen School of Medicine at UCLA.
Evelyn ArambulaDepartment of Radiation Oncology, David Geffen School of Medicine at UCLA.
Aparna BhaduriJonsson Comprehensive Cancer Center at UCLA.
Harley I KornblumJonsson Comprehensive Cancer Center at UCLA.
Frank PajonkDepartment of Radiation Oncology, David Geffen School of Medicine at UCLA.ORCID 0000-0003-4067-9751

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
Shared Resource Core: Single Cell AnalysisU54CA217378 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI LANDER, ARTHUR D · 2018 to 2022
$9.7M
UCI P30 Skin Center Systems Biology CoreP30AR075047 · NIAMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI ANDERSEN, BOGI, GANESAN, ANAND K · 2019 to 2025
$5.1M
Use of CTEP portfolio compounds to counteract phenotype conversion in GBMR01CA260886 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Frank Pajonk · 2022 to 2026
$2.6M
Utilizing Radiation-Induced Multi-potency to Increase the Efficacy of RadiotherapyR01CA281682 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Frank Pajonk · 2023 to 2026
$2.0M
PacBio RS Single Molecule, Real-Time (SMRT) DNA SequencerS10OD010794 · OD · UNIVERSITY OF CALIFORNIA-IRVINE · PI SANDMEYER, SUZANNE · 2012 to 2012
$600k
High-Throughput DNA SequencerS10OD021718 · OD · UNIVERSITY OF CALIFORNIA-IRVINE · PI SANDMEYER, SUZANNE · 2016 to 2016
$600k
High Throughput DNA SequencerS10RR025496 · NCRR · UNIVERSITY OF CALIFORNIA-IRVINE · PI SANDMEYER, SUZANNE · 2009 to 2009
$500k
NCI NIH HHS P30 CA062203NCI NIH HHS R01 CA260886NCI NIH HHS R01 CA281682NCI NIH HHS U54 CA217378NCRR NIH HHS S10 RR025496NIAMS NIH HHS P30 AR075047NIH HHS S10 OD010794NIH HHS S10 OD021718
6 · The paper itself

Abstract

Glioblastoma is the deadliest brain cancer in adults and almost all patients succumb to the tumor. While surgery followed by chemo-radiotherapy significantly delays disease progression, these treatments do not lead to long-term tumor control and targeted therapies or biologics have so far failed to further improve survival. Utilizing a transient radiation-induced state of multipotency we used the adenylcyclase activator forskolin to alter the cellular fate of glioma cells in response to radiation. The combined treatment induced the expression of neuronal markers in glioma cells, reduced proliferation and led to a distinct gene expression profile. scRNAseq revealed that the combined treatment forced glioma cells into a microglia- and neuron-like phenotypes.

Indexed as

cAMPdifferentiation therapyforskolinGlioblastomamouse modelradiationscRNAseqsurvival

Identifiers

PMID38798647
PMCPMC11118449

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.